{"DataElement":{"publicId":"6706633","version":"1","preferredName":"Individual Pharmacokinetic Study Coagulation Factor IX  Extended Half Life One-Stage Clotting Factor Assay","preferredDefinition":"Individual; a single human being._A study of the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body._Coagulation factor IX (461 aa, ~52 kDa) is encoded by the human F9 gene. This protein plays a role in the intrinsic pathway of blood coagulation through the mediation of proteolysis that converts factor X into an active protease._The amount of time needed for a material to lose half of its physical, chemical, or biological activity._To increase in length or duration._A clotting factor assay where FVIII?deficient plasma is added to test plasma and the APTT reagent, mixed and incubated for 3?5 min. The mixture is then recalcified, and the coagulation time is recorded and compared to a standard curve.","longName":"Indi_Phar_Coag_Exte_Half_67328","context":"PhenX","contextVersion":"1","DataElementConcept":{"publicId":"6706632","version":"1","preferredName":"Individual Pharmacokinetic Study Coagulation Factor IX  Extended Half Life","preferredDefinition":"Individual; a single human being._A study of the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body._Coagulation factor IX (461 aa, ~52 kDa) is encoded by the human F9 gene. This protein plays a role in the intrinsic pathway of blood coagulation through the mediation of proteolysis that converts factor X into an active protease._The amount of time needed for a material to lose half of its physical, chemical, or biological activity._To increase in length or duration.","longName":"Indi_Phar_Coag_Exte_Half","context":"PhenX","contextVersion":"1","ObjectClass":{"publicId":"6706625","version":"1","preferredName":"Individual Pharmacokinetic Study","preferredDefinition":"Individual; a single human being.:A study of the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body.","longName":"C0237401:C49663","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Individual","conceptCode":"C0237401","definition":"Individual; a single human being.","evsSource":"UMLS_CUI","primaryIndicator":"No","displayOrder":"1"},{"longName":"Pharmacokinetic Study","conceptCode":"C49663","definition":"A study of the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"871621AB-70A8-1BF3-E053-F662850AB237","latestVersionIndicator":"Yes","beginDate":"2019-04-21","endDate":null,"createdBy":"PANH","dateCreated":"2019-04-21","modifiedBy":"ONEDATA","dateModified":"2019-04-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6706630","version":"1","preferredName":"Coagulation Factor IX Extend Half Life","preferredDefinition":"Coagulation factor IX (461 aa, ~52 kDa) is encoded by the human F9 gene. This protein plays a role in the intrinsic pathway of blood coagulation through the mediation of proteolysis that converts factor X into an active protease.:To increase in length or duration.:The amount of time needed for a material to lose half of its physical, chemical, or biological activity.","longName":"C28482:C25270:C70916","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Coagulation Factor IX","conceptCode":"C28482","definition":"Coagulation factor IX (461 aa, ~52 kDa) is encoded by the human F9 gene. This protein plays a role in the intrinsic pathway of blood coagulation through the mediation of proteolysis that converts factor X into an active protease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Extend","conceptCode":"C25270","definition":"To increase in length or duration.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Half Life","conceptCode":"C70916","definition":"The amount of time needed for a material to lose half of its physical, chemical, or biological activity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"87158879-CB5F-1C0B-E053-F662850A3B41","latestVersionIndicator":"Yes","beginDate":"2019-04-21","endDate":null,"createdBy":"PANH","dateCreated":"2019-04-21","modifiedBy":"ONEDATA","dateModified":"2019-04-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008557","version":"1","preferredName":"Lab Results","preferredDefinition":"the results of laboratory tests.","longName":"LAB_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2CFBA7D-D009-7227-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"87158879-CB70-1C0B-E053-F662850A3B41","latestVersionIndicator":"Yes","beginDate":"2019-04-21","endDate":null,"createdBy":"PANH","dateCreated":"2019-04-21","modifiedBy":"PANH","dateModified":"2019-08-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6732888","version":"1","preferredName":"One-Stage Clotting Factor Assay","preferredDefinition":"A clotting factor assay where FVIII?deficient plasma is added to test plasma and the APTT reagent, mixed and incubated for 3?5 min. The mixture is then recalcified, and the coagulation time is recorded and compared to a standard curve.","longName":"6732888v1.0","context":"PhenX","contextVersion":"1","type":"Non-enumerated","dataType":"NUMBER","minLength":null,"maxLength":null,"minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2008557","version":"1","preferredName":"Lab Results","preferredDefinition":"the results of laboratory tests.","longName":"LAB_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2CFBA7D-D009-7227-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6732887","version":"1","preferredName":"One-Stage Clotting Factor Assay","preferredDefinition":"A clotting factor assay where FVIII‐deficient plasma is added to test plasma and the APTT reagent, mixed and incubated for 3–5 min. The mixture is then recalcified, and the coagulation time is recorded and compared to a standard curve.","longName":"C159550","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"One-Stage Clotting Factor Assay","conceptCode":"C159550","definition":"A clotting factor assay where FVIII-deficient plasma is added to test plasma and the APTT reagent, mixed and incubated for 3-5 min. The mixture is then recalcified, and the coagulation time is recorded and compared to a standard curve.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"876F43BC-40A9-5EB3-E053-F662850A4510","latestVersionIndicator":"Yes","beginDate":"2019-04-26","endDate":null,"createdBy":"PANH","dateCreated":"2019-04-26","modifiedBy":"ONEDATA","dateModified":"2019-04-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"876F43BC-40BA-5EB3-E053-F662850A4510","latestVersionIndicator":"Yes","beginDate":"2019-04-26","endDate":null,"createdBy":"PANH","dateCreated":"2019-04-26","modifiedBy":"PANH","dateModified":"2019-08-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2793652","version":"1","longName":"PhenX","context":"PhenX","ClassificationSchemeItems":[{"publicId":"6641385","version":"1","longName":"Hemophilia","context":"PhenX"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Data Element Individual Pharmacokinetic Study Coagulation Factor IX  Extended Half Life One-Stage Clotting Factor Assay does not have Preferred Question Text","type":"Preferred Question Text","description":"Data Element Individual Pharmacokinetic Study Coagulation Factor IX  Extended Half Life One-Stage Clotting Factor Assay does not have Preferred Question Text","url":null,"context":"PhenX"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"87158879-CB82-1C0B-E053-F662850A3B41","latestVersionIndicator":"Yes","beginDate":"2019-04-21","endDate":null,"createdBy":"PANH","dateCreated":"2019-04-21","modifiedBy":"PANH","dateModified":"2020-06-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}